Bulk Pharmaceutical API Sources for RIMACTANE

Bulk Pharmaceutical API Sources for RIMACTANE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		R7382_SIGMA
Sigma-Aldrich		83907_SIGMA
Sigma-Aldrich		R3501_SIGMA
Molport		MolPort-002-513-586
TimTec		ST057531
AKos Consulting & Solutions		AKOS015951372

RIMACTANE Bulk Active Pharmaceutical Ingredient (API) Sourcing and Patent Landscape

Last updated: February 19, 2026

This report analyzes the bulk active pharmaceutical ingredient (API) sourcing landscape and patent status for RIMACTANE, a brand name for rifampicin. The analysis focuses on identifying key manufacturers, examining patent expiry dates, and understanding regulatory considerations relevant to API procurement.

What is RIMACTANE (Rifampicin) and Its Therapeutic Use?

RIMACTANE is a brand name for rifampicin, an antibiotic used in the treatment and prevention of tuberculosis (TB). It is also employed for prophylaxis against meningococcal meningitis and Haemophilus influenzae type b (Hib) infections. Rifampicin is a bactericidal agent that inhibits bacterial DNA-dependent RNA polymerase [1]. Its efficacy against Mycobacterium tuberculosis makes it a cornerstone of multi-drug therapy for TB.

Who are the Primary Manufacturers of Rifampicin API?

The production of rifampicin API is concentrated among several global manufacturers. These companies supply the active ingredient to pharmaceutical firms for formulation into finished dosage forms. Key manufacturers include:

• Teva Pharmaceutical Industries Ltd.: A leading global generic pharmaceutical company with significant API manufacturing capabilities.
• Lupin Limited: An Indian multinational pharmaceutical company with a strong presence in API production, particularly for antibiotics.
• Dr. Reddy's Laboratories Ltd.: Another major Indian pharmaceutical company that manufactures a wide range of APIs, including rifampicin.
• Aurobindo Pharma Limited: An Indian vertically integrated pharmaceutical company with substantial API manufacturing facilities.
• Sandoz International GmbH: A subsidiary of Novartis, Sandoz is a global leader in generic pharmaceuticals and biosimilars, with a broad API portfolio.
• Amneal Pharmaceuticals LLC: A US-based generics manufacturer that has expanded its API sourcing and manufacturing operations.
• Cadila Healthcare Ltd. (Zydus Lifesciences): An Indian pharmaceutical company with integrated operations from API to finished formulations.

These manufacturers often operate under strict regulatory oversight, including Good Manufacturing Practices (GMP) certifications from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Sourcing decisions typically involve assessing manufacturing capacity, quality control systems, regulatory compliance, and cost.

What is the Patent Status of Rifampicin?

Rifampicin, as a compound, is off-patent globally. Its original patents have long expired. However, patents may exist for specific formulations, novel delivery systems, combination therapies, or manufacturing processes.

Key Patent Expiry Information:

• Compound Patent for Rifampicin: The original compound patents for rifampicin expired in the late 1970s and early 1980s. This means the basic molecule can be manufactured and sold by any entity that meets regulatory requirements.
• Newer Formulation/Process Patents: While the compound is generic, pharmaceutical companies may have filed patents on:
  • Novel Formulations: For example, extended-release versions, fixed-dose combinations with other anti-TB drugs (e.g., rifampicin/isoniazid/pyrazinamide).
  • Manufacturing Processes: Proprietary methods for synthesizing rifampicin that offer improved yield, purity, or reduced environmental impact.
  • Specific Polymorphs: Different crystalline forms of rifampicin that may have altered dissolution or stability properties.

A thorough patent landscape analysis for specific rifampicin-containing products or advanced manufacturing techniques is recommended for a precise understanding of current intellectual property constraints. The absence of compound patent protection for rifampicin has facilitated its widespread availability as a generic API.

What are the Regulatory Considerations for Rifampicin API Sourcing?

Sourcing rifampicin API involves navigating a complex regulatory environment designed to ensure product quality, safety, and efficacy. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): API manufacturers must adhere to GMP guidelines established by major regulatory bodies such as the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and WHO. This ensures consistency in manufacturing processes and quality control.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF provides confidential detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Certificate of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API complies with the requirements of the European Pharmacopoeia. This simplifies the regulatory approval process for finished products in Europe.
• Pharmacopoeial Standards: Rifampicin API must meet the specifications outlined in relevant pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define critical quality attributes such as identity, purity, assay, and impurity limits.
• Impurity Profiling: Regulatory agencies place significant emphasis on the control of impurities in APIs. Manufacturers must identify, quantify, and control process-related impurities and degradation products to ensure patient safety. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (e.g., ICH Q3A(R2)) are critical here.
• Supply Chain Integrity: Ensuring the integrity of the API supply chain is paramount. This includes preventing counterfeiting, ensuring proper storage and transportation conditions, and conducting thorough audits of API suppliers.
• Country-Specific Registrations: Depending on the target market for the finished drug product, API manufacturers may need to register their DMFs or obtain specific approvals in various countries, including those with stringent requirements like the US, EU, and Japan, as well as emerging markets.

How Does API Quality Impact Finished Product Development?

The quality of the rifampicin API is directly linked to the safety, efficacy, and stability of the final drug product. Key aspects of API quality that impact finished product development include:

• Purity and Impurity Profile: Inconsistent API purity or the presence of uncontrolled impurities can lead to batch failures, reduced efficacy, or adverse patient reactions. Understanding and controlling process-related impurities and degradation products is critical for formulation development and stability studies. For rifampicin, specific impurities like rifampicin quinone and rifampicin N-oxide are of concern and must be monitored.
• Physical Properties: Particle size distribution, crystal form (polymorphism), and flowability of the API significantly influence the formulation process. These properties affect blending, compression, dissolution rates, and bioavailability of the finished dosage form. For instance, a consistent particle size is crucial for achieving uniform content in tablets.
• Stability: The inherent stability of the API under various storage conditions (temperature, humidity, light) dictates the shelf-life and storage requirements of the finished product. Rifampicin is known to be sensitive to moisture and light, necessitating appropriate handling and storage.
• Solubility and Dissolution Rate: These are critical for oral dosage forms. The API's dissolution profile directly impacts the rate at which the drug is absorbed into the bloodstream, affecting its therapeutic outcome. Formulation strategies are often employed to enhance dissolution if the inherent API properties are suboptimal.
• Batch-to-Batch Consistency: Reliable and reproducible API manufacturing ensures that each batch of the finished product will perform as expected. Variability in API quality can lead to significant challenges in manufacturing scale-up and regulatory submissions.
• Regulatory Compliance: Sourcing API from manufacturers with robust quality systems and regulatory compliance (e.g., GMP certifications, approved DMFs) reduces the risk of regulatory delays or rejections during the drug product approval process.

What are the Sourcing Strategies for Rifampicin API?

Effective sourcing strategies for rifampicin API are crucial for ensuring a stable, cost-effective, and compliant supply chain. These strategies involve:

• Dual/Multiple Sourcing: Establishing relationships with at least two qualified API manufacturers mitigates supply chain risks associated with single-source dependencies, such as production disruptions, quality issues, or geopolitical instability.
• Supplier Qualification and Auditing: A rigorous process for selecting and qualifying API suppliers is essential. This includes assessing their manufacturing capabilities, quality management systems, regulatory history, financial stability, and ethical practices through on-site audits.
• Long-Term Supply Agreements: Negotiating long-term contracts with key suppliers can ensure price stability, guaranteed supply volumes, and foster closer collaborative relationships. These agreements should clearly define quality specifications, delivery schedules, and change control procedures.
• Geographic Diversification: Sourcing APIs from manufacturers located in different geographic regions can reduce vulnerability to localized disruptions, such as natural disasters, trade disputes, or political unrest.
• Cost-Benefit Analysis: While cost is a significant factor, it must be balanced against quality, reliability, and regulatory compliance. The lowest-cost supplier may not always be the most advantageous if it compromises these critical elements.
• Risk Management: Proactive identification and mitigation of supply chain risks are vital. This includes monitoring geopolitical developments, economic trends, and regulatory changes that could impact API availability or cost.
• Quality Agreements: Implementing comprehensive Quality Agreements between the drug product manufacturer and the API supplier formalizes responsibilities for quality control, change management, complaint handling, and regulatory compliance.

The availability of rifampicin as a generic API with expired compound patents allows for a competitive sourcing environment. However, the importance of stringent quality control and regulatory adherence remains paramount.

Key Takeaways

• Rifampicin, the API for RIMACTANE, is a well-established, off-patent antibiotic critical for tuberculosis treatment.
• Major API manufacturers, primarily based in India and Europe, dominate the global supply.
• While compound patents have expired, newer patents may exist for specific formulations or manufacturing processes.
• Rigorous adherence to GMP, pharmacopoeial standards, and impurity control is mandatory for API sourcing.
• API quality directly impacts finished product safety, efficacy, and regulatory approval.
• Strategic sourcing involves dual sourcing, robust supplier qualification, long-term agreements, and geographic diversification to ensure supply chain resilience.

Frequently Asked Questions

1. Can new patents impact the availability of rifampicin API? While the basic rifampicin compound is generic, patents on novel formulations (e.g., combination therapies, extended-release) or proprietary manufacturing processes could influence the market for specific rifampicin-containing products, but not the availability of the bulk API itself for generic use.

2. What are the most common quality issues encountered with rifampicin API? Common quality issues include inconsistent particle size distribution impacting dissolution, presence of specified impurities (e.g., rifampicin quinone, rifampicin N-oxide) exceeding pharmacopoeial limits, and inadequate control of residual solvents or heavy metals.

3. How does regulatory scrutiny of API DMFs affect sourcing decisions? Regulatory agencies like the FDA and EMA review DMFs as part of drug product applications. A DMF that is incomplete, outdated, or associated with a history of manufacturing non-compliance can lead to significant delays or rejections in drug product approval, making suppliers with well-maintained DMFs highly desirable.

4. What is the typical lead time for procuring large quantities of rifampicin API? Lead times can vary significantly based on the manufacturer's current production schedule, existing inventory, and the size of the order, but generally range from 2 to 6 months for substantial bulk orders from qualified suppliers.

5. Are there specific regional advantages or disadvantages in sourcing rifampicin API? Indian manufacturers often offer competitive pricing due to economies of scale and established manufacturing infrastructure. European suppliers may offer perceived advantages in terms of stringent regulatory compliance and proximity to key markets, though often at a higher cost. Diversifying sourcing across regions mitigates individual market risks.

Cited Sources

[1] Tuberculosis (TB) - Overview. (n.d.). Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/tb/topic/treatment/treatmentoverview.htm